The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ.

[1]  D. Rea,et al.  Low grade Ductal Carcinoma in situ (DCIS): how best to describe it? , 2014, Breast.

[2]  H. Hense,et al.  Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ. , 2014, Radiology.

[3]  S. Pinder,et al.  Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ , 2013 .

[4]  J. Cuzick,et al.  Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence , 2013, Clinical Cancer Research.

[5]  D. Ravichandran,et al.  Ductal carcinoma in situ of the breast: is clinical follow-up necessary after treatment? , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[7]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.

[8]  L. Fallowfield,et al.  Time for a low-risk DCIS trial: harnessing public and patient involvement. , 2012, The Lancet. Oncology.

[9]  G. Ball,et al.  The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS , 2012, British Journal of Cancer.

[10]  P. Gøtzsche,et al.  The Breast Screening Programme and misinforming the public , 2011, Journal of the Royal Society of Medicine.

[11]  P. Gøtzsche,et al.  Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? , 2011, Radiology.

[12]  S. Duffy,et al.  Mammographic screening and "overdiagnosis". , 2011, Radiology.

[13]  D. Sgroi,et al.  The molecular pathology of breast cancer progression , 2011, The Journal of pathology.

[14]  M. J. van de Vijver,et al.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast , 2007, British Journal of Cancer.

[15]  A. Vingerhoets,et al.  A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. , 2007, European journal of cancer.

[16]  I. Ellis,et al.  The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal , 2006, Journal of Clinical Pathology.

[17]  M. H. Pappworth.  Modern Hippocratic Oath , 1971 .